Related Experiment Video

Updated: May 1, 2026

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.7K

Bexarotene prodrugs: targeting through cleavage by NQO1 (DT-diaphorase)

Anja Schäfer1, Ethan S Burstein2, Roger Olsson3

  • 1Department of Chemistry and Molecular Biology/Medicinal Chemistry, University of Gothenburg, SE-412 96 Gothenburg, Sweden.

Bioorganic & Medicinal Chemistry Letters
|March 27, 2014
PubMed

Insights

Researchers developed a novel bexarotene prodrug targeting neurodegenerative diseases. This strategy utilizes the enzyme NAD(P)H/quinone oxidoreductase (NQO1) for targeted drug release in the brain, minimizing peripheral exposure.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Drug Discovery

Background:

  • Bexarotene, a retinoid X receptor (RXR) agonist, shows potential for treating neurodegenerative diseases.
  • Current treatments face challenges with widespread peripheral exposure and limited brain penetration.

Purpose of the Study:

  • To design a targeted drug delivery system for bexarotene to enhance efficacy in neurodegenerative conditions.
  • To develop a prodrug strategy leveraging the enzyme NAD(P)H/quinone oxidoreductase (NQO1), which is upregulated in affected brain regions.

Main Methods:

  • Synthesis of a series of indolequinone-based prodrugs designed as substrates for NQO1.
  • Coupling of bexarotene to indolequinone moieties to create novel prodrugs.
  • Enzymatic assays to evaluate prodrug cleavage by NQO1 and esterases.

Main Results:

  • Bexarotene-3-(hydroxymethyl)-5-methoxy-1,2-dimethyl-1H-indole-4,7-dione ester 7a demonstrated optimal cleavage by NQO1.
  • The synthesized prodrugs were found to be stable against esterase activity.
  • This indicates selective activation by NQO1 in targeted tissues.

Conclusions:

  • A novel bexarotene prodrug strategy was successfully developed, enabling targeted drug release in the brain.
  • The NQO1-activated prodrugs offer a promising approach to improve bexarotene's therapeutic index for neurodegenerative diseases.
  • This targeted delivery system minimizes off-target effects and enhances treatment efficacy.
Keywords:
Alzheimer’s diseaseBexaroteneDisease targetingParkinson’s diseaseProdrugsdt diaphorase

More Related Videos

Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites05:28

Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites

Published on: June 2, 2023

3.1K
Aptamer-Based Target Detection Facilitated by a 3-Stage G-Quadruplex Isothermal Exponential Amplification Reaction03:38

Aptamer-Based Target Detection Facilitated by a 3-Stage G-Quadruplex Isothermal Exponential Amplification Reaction

Published on: October 6, 2022

1.6K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
3.7K
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems01:19

Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems

Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
948
Prodrugs01:30

Prodrugs

Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
4.1K
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.7K